ORIGINAL RESEARCH
Cardiology
doi: 10.25005/2074-0581-2025-27-3-613-623
THE SIGNIFICANCE OF CERTAIN PRO-ATHEROGENIC AND PRO-INFLAMMATORY MARKERS FOR EARLY DIAGNOSIS AND RISK STRATIFICATION OF ATHEROSCLEROSIS IN YOUNG AND MIDDLE-AGED INDIVIDUALS

A.M. NAMITOKOV1,2, I.V. GILEVICH1,2, K.V. KARABAKHTSIEVA2

1Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1, Krasnodar, Russian Federation
2Kuban State Medical University, Krasnodar, Russian Federation

Objective: To assess key proatherogenic and inflammatory biomarkers related to the severity of atherosclerosis in patients with early stable disease.

Methods: The study involved 86 participants, including 65 patients with early stable atherosclerosis and 21 healthy volunteers. All participants had their lipid-related marker levels of Lp(a), ApoB, ANGPTL3, and Lp-PLA2 measured, along with several novel inflammation markers: SIRI, SII, NLR, PLR, and MLR. The participants in the study were divided into three groups based on the number of arterial segments affected by plaque. The arteries examined included coronary, brachiocephalic, iliac, and common femoral arteries on both the right and left sides. The groups were categorized as follows: those with no affected segments (none of plaque burden), those with 1 to 3 affected segments (moderate plaque burden), and those with four or more affected segments (severe plaque burden). The data were analyzed using one-way analysis of variance (ANOVA), Spearman rank correlation, and logistic regression.

Results: Higher levels of Lp(a), Lp-PLA2, and ApoB were linked to increased severity of atherosclerosis, whereas HDL-C levels exhibited a protective effect. Inflammatory markers (SIRI, NLR) showed a positive correlation with the severity of atherosclerosis.

Conclusion: Lipid-related and inflammatory markers are closely linked to the severity of atherosclerotic lesions, emphasizing their potential for early diagnosis and risk assessment. Larger cohort studies are necessary to validate these findings.

Keywords: Atherosclerosis biomarkers, inflammatory markers, atherosclerosis, lipoprotein (a).

Download file:

References
  1. Namitokov A, Karabakhtsieva K. Circumventing cardiovascular calamities: The dawn of ANGPTL3 blockade in severe dyslipidemia management. Cardiovasc He- matol Disord Drug Targets. 2024;24(2):59-64. https://doi.org/10.2174/0118715 29X305291240715112812
  2. Namitokov A. Sortilin and its potential role in cardiovascular pathology. Egypt Heart J. 2024;76:78. https://doi.org/10.1186/s43044-024-00512-3
  3. Benimetskaya KS, Shramko VS, Stakhneva EM, Makarenkova KV, Shcherbakova LV, Ragino YuI, i dr. Assotsiatsiya lipoprotein-assotsiirovannoy fosfolipazy A2 (Lp-Pla2) s proproteinnovoy konvertazoy subtilisin/keksin tipa 9 (PCSK9) pri semeynoy giperkholesterinemii [Association of lipoprotein-associated phospholipase A2 (Lp-Pla2) with proprotein convertase subtilisin/kexin type 9 (Pcsk9) in familial hypercholesterolemia]. Ateroskleroz. 2019;15(1):15-23. https://doi.org/10.15372/ATER20190102
  4. Dabrowska AM, Tarach JS, Wojtysiak-Duma B, Duma D. Fetuin-A (AHSG) and its usefulness in clinical practice. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(3):352-9. https://doi.org/10.5507/bp.2015.018
  5. Talibova SM, Basieva MA, Shvartz VA. Rol’ “novykh” biomarkyorov sistemnogo vospaleniya v prognozirovanii kharaktera techeniya ishemicheskoy bolezni serdtsa i rezul’tatov revaskulyarizatsii miokarda [The role of “novel” biomarkers of systemic inflammation in assessing the severity and course of coronary heart disease]. Klinicheskaya fiziologiya krovoobrashcheniya. 2023;20(3):221-30. https://doi.org/10.24022/1814-6910-2023-20-3-221-230
  6. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J. 2010;31(23):2844-53. https://doi.org/10.1093/eurheartj/ehq386
  7. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-46. https://doi.org/10.1093/eurheartj/ehac361
  8. Langsted A, Nordestgaard BG, Kamstrup PR. Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study. Eur Heart J. 2021;42(12):1147-56. https://doi.org/10.1093/eurheartj/ehaa1085
  9. Taylor HA, Deumite NJ, Chaitman BR, Davis KB, Killip T, Rogers WJ. Asymptomatic left main coronary artery disease in the Coronary Artery Surgery Study (CASS) registry. Circulation. 1989;79(6):1171-9. https://doi.org/10.1161/01. cir.79.6.1171
  10. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301-10. https://doi.org/10.1056/NEJMoa064278
  11. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22. https://doi.org/10.1016/ S0140-6736(10)60484-9
  12. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626-35. https://doi.org/10.1016/S0140-6736(14)61177-6
  13. Huang F, Wang K, Shen J. Lipoprotein-associated phospholipase A2: The story continues. Med Res Rev. 2020;40(1):79-134. https://doi.org/10.1002/med.21597
  14. Dimitroglou Y, Sakalidis A, Mavroudis A, Kalantzis C, Valatsou A, Andrikou I, et al. Lipoprotein-associated phospholipase A2 in coronary artery disease. Current Topics in Medicinal Chemistry. 2022;22(28):2344-54. https://doi.org/10.2174/15 68026623666221027145545
  15. Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363(23):2220-7. https://doi.org/10.1056/NEJMoa1002926
  16. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-43. https://doi.org/10.1161/hc0902.104353
  17. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-31. https://doi.org/10.1056/NEJMoa1707914
  18. Xia Y, Xia C, Wu L, Li Z, Li H, Zhang J. Systemic immune inflammation index (SII), system inflammation response index (SIRI) and risk of all-cause mortality and cardiovascular mortality: A 20-year follow-up cohort study of 42,875 US adults. J Clin Med. 2023;12(3):1128. https://doi.org/10.3390/jcm12031128
  19. Kondo T, Nakano Y, Adachi S, Murohara T. Effects of tobacco smoking on cardiovascular disease. Circ J. 2019;83(10):1980-5. https://doi.org/10.1253/circj. CJ-19-0323
  20. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet. 2004;364(9438):937-52. https:// doi.org/10.1016/S0140-6736(04)17018-9
  21. Ali MK, Pearson-Stuttard J, Selvin E, Gregg EW. Interpreting global trends in type 2 diabetes complications and mortality. Diabetologia. 2022;65(1):3-13. https:// doi.org/10.1007/s00125-021-05585-2
  22. Yang WY, Melgarejo JD, Thijs L, Zhang ZY, Boggia J, Wei FF, et al. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA. 2019;322(5):409-20. https://doi.org/10.1001/jama.2019.9811
  23. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: Updated systematic review and meta-analysis. Lancet. 2016;387(10017):435-43. https://doi.org/10.1016/S0140-6736(15)00805-3

Authors' information:

Namitokov Alim Muratovich,
Candidate of Medical Sciences, Head of the Cardiology Department No. 2 for Patients with Myocardial Infarction, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Associate Professor of the Department of Therapy No. 1, Kuban State Medical University
Researcher ID: A-4401-2019
Scopus ID: 57164765500

ORCID ID: 0000-0002-5866-506X
SPIN: 6937-7443
E-mail: namitokov.alim@gmail.com

Gilevich Irina Viktorovna,
Candidate of Medical Sciences, Head of the Research Laboratory of Regenerative Medicine, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Assistant of the Department of Oncology with a Course of Thoracic Surgery, Kuban State Medical University
ORCID ID: 0000-0002-9766-1811
E-mail: giliv@list.ru

Karabakhtsieva Karina Vitalievna,
Cardiologist, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1
ORCID ID: 0000-0002-1543-2987
E-mail: karina26051998@gmail.com

Information about support in the form of grants, equipment, medications

The authors did not receive financial support from manufacturers of medicines and medical equipment

Conflicts of interest: No conflict

Address for correspondence:

Namitokov Alim Muratovich
Candidate of Medical Sciences, Head of the Cardiology Department No. 2 for Patients with Myocardial Infarction, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Associate Professor of the Department of Therapy No. 1, Kuban State Medical University

350086, Russian Federation, Krasnodar, 1 Maya str., 167

Tel.: +7 (961) 5317226

E-mail: namitokov.alim@gmail.com


This work is licensed under a Creative Commons Attribution 4.0 International License.

Materials on the topic:
  1. CORONARY ARTERY ECTASIA: CURRENT CONCEPTS
  2. DYSLIPIDEMIA AND SEVERITY OF ATHEROSCLEROTIC CORONARY ARTERY DISEASE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND SUBCLINICAL HYPOTHYROIDISM
  3. PREVALENCE OF CORONARY ARTERY DISEASE IN YOUNG AND MIDDLE AGE PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION
  4. SOME FEATURES OF PERIPHERAL BLOOD COMPOSITION IN PATIENTS WITH CORONARY ARTERY DISEASE AND ARTERIAL HYPERTENSION
  5. COMPARATIVE ANALYSIS OF C-REACTIVE PROTEIN AND RED BLOOD CELLS DISTRIBUTION WIDTH LEVELS IN SUBGROUPS DEPENDING ON THE SEVERITY OF HYPERLIPIDEMIA ACCORDING TO LABORATORY REGISTRY DATA
  6. CORONARY ARTERY CALCIFICATION IN LIVER TRANSPLANT RECIPIENTS
  7. GENETIC ASPECTS OF ATRIAL FIBRILLATION ON THE BACKGROUND OF ARTERIAL HYPERTENSION IN COMBINATION WITH NONCARDIAC DISEASES
  8. APPLICATION OF A TWO-STEP SCREENING SYSTEM IN COMPLEX EVALUATION OF PSYCHOSOCIAL STATUS IN PATIENTS WITH CORONARY HEART DISEASE
  9. FEATURES OF REMODELLING OF THE LEFT VENTRICULAR MYOCARDIUM IN PATIENTS WITH ARTERIAL HYPERTENSION OF ELDERLY AGE WITH COMORBID DEPRESSION
  10. TREATMENT OF CHRONIC HEART FAILURE IN MIDDLE-AGED MEN WITH DEPRESSION

◄ Back to the list